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Abstract
Background: Differential diagnosis between sepsis and non-infectious inflammatory disorders demands improved
biomarkers. Soluble Triggering Receptor Expression on Myeloid cells (sTREM-1) is an activating receptor whose role
has been studied throughout the last decade. We performed a systematic review to evaluate the accuracy of
plasma sTREM-1 levels in the diagnosis of sepsis in children with Systemic Inflammatory Response Syndrome (SIRS).
Methods: A literature search of PubMed, Cochrane Central Register of Controlled Trials, Cumulative Index to
Nursing and Allied Health Literature (CINAHL) and ISI Web of Knowledge databases was performed using specific
search terms. Studies were included if they assessed the diagnostic accuracy of plasma sTREM-1 for sepsis in
paediatric patients with SIRS. Data on sensitivity, specificity, positive predictive value, negative predictive value, area
under receiver operating characteristic curve were extracted. The methodological quality of each study was
assessed using a checklist based on the Quality Assessment Tool for Diagnostic Accuracy Studies.
Results: Nine studies comprising 961 patients were included, four of which were in newborns, three in children
and two in children with febrile neutropenia. Some data from single studies support a role of sTREM-1 as a
diagnostic tool in pediatric sepsis, but cannot be considered conclusive, because a quantitative synthesis was not
possible, due to heterogeneity in studies design.
Conclusions: This systematic review suggests that available data are insufficient to support a role for sTREM in the
diagnosis and follow-up of paediatric sepsis.
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Background
Sepsis is a syndrome proceeding from Systemic Inflam-
matory Response Syndrome (SIRS) to invasive infection.
A rampant host response can progress to shock and
multiple organ failure mediated by immunity, coagula-
tion and intermediate metabolism [1]. Early recognition
of sepsis is fundamental in children and adults, since it
is still one of the principal causes of death in both popu-
lations [2], despite all available antimicrobial and sup-
portive therapies [3].
The pathogenesis of sepsis is complex and not yet fully
understood [4]. The first defence against pathogens con-
sists of innate immunity, which prevents dissemination
of infection until the adaptive response can occur. While
activated, neutrophils and monocytes/macrophages re-
lease pro-inflammatory cytokines, attempting to control
the infection; an excessive and dysregulated production of
cytokines can lead to SIRS and tissue damage. A fine regu-
lation of innate immunity is crucial and several attempts
have been made to clarify this complex mechanism [5].
Among several candidate receptors, Triggering Receptor
Expressed on Myeloid cells 1 (TREM-1) appears to play a
relevant role in the modulation of innate immunity, amp-
lifying or attenuating Toll-Like Receptor (TLR)-induced
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signals [6, 7]. TREM-1 is a receptor of the immunoglobu-
lin superfamily, expressed on human neutrophils and
monocytes [6]. In the early phase of infection, the engage-
ments of Pattern Recognition Receptors (PRRs) by micro-
bial components induce up-regulation of TREM-1. After
recognition of a still unknown ligand, TREM-1 associates
with a signal transduction molecule called DAP12, trigger-
ing the sustained release of pro-inflammatory cytokines
(TNF-alpha and IL-1b) and chemokines (IL-8 and mono-
cyte chemotactic protein), which may result in prolonged
survival of neutrophils and monocytes at the inflammatory
site [8]. TREM-1 activation by itself induces only a modest
cellular activation and mediator release, whereas its activa-
tion in synergy with TLRs [9] and NOD-like receptors
[10] results in a substantial amplification of the immune
response. TREM-1 expression was found to be high in the
context of inflammatory responses induced by bacterial
and fungal infections [11]. More recent data have linked
TREM-1 to inflammatory bowel disease, pancreatitis and
other non-infectious conditions, calling the idea of a spe-
cificity of the TREM-1 pathway into question [12]. Apart
from inducing a marked increase in TREM-1 expression,
sepsis also induces a soluble form of TREM-1 (sTREM-1),
detectable in biological fluids. It is unclear whether
sTREM-1 derives from alternative splicing producing se-
creted receptors isoforms or from the cleavage of extracel-
lular domains of the receptor [6]. However, both cell
surface TREM-1 and sTREM-1 are up-regulated during
sepsis: due to the undemanding method required to dose
the soluble form, this protein has been proposed for the
diagnosis of infection in the clinical setting.
Some reviews in adults have investigated the role of
TREM-1 in differentiating between infectious and non-
infectious conditions. Two previous meta-analyses have
found sTREM-1 as a potentially effective biomarker in
bacterial infections [13] or bacterial pleural effusions
[14]. A recent review examined the role of sTREM-1 in
the diagnosis of sepsis in adults [15]. The authors found
that sTREM-1 had moderate diagnostic value in differ-
entiating sepsis from SIRS. Specifically, plasma sTREM-
1 alone was not considered sufficient for the diagnosis of
sepsis in patients with SIRS. Several studies have ad-
dressed the role of sTREM-1 in paediatric patient popu-
lations. However, these results have never been pooled.
Our objective was to systematically review the current
level of evidence on sTREM-1 as a diagnostic tool in
paediatric sepsis.
Methods
This work was carried out within the Global Research in
Paediatrics (GRiP) framework, an international, EU-
funded project aimed at improving the methodology of
paediatric research. The authors are involved with the im-
plementation of research methodologies on biomarkers in
paediatric sepsis. The study protocol has been agreed
within the GRiP framework and has been previously
published (http://www.grip-network.org/index.php/cms/en/
tools_for_interoperability). This systematic review is in
compliance with the PRISMA statement [16].
Search strategy
A systematic literature search of the PubMed/MEDLINE,
Cochrane Library, Cumulative Index to Nursing and
Allied Health Literature (CINAHL) and ISI Web of
Knowledge databases was carried out, targeting articles
assessing sTREM-1 as a diagnostic test for paediatric
sepsis. A search algorithm based on a combination of
the following terms was used: Systemic Inflammatory
Response Syndrome, Bacteraemia, Sepsis, Bacterial in-
fections/diagnosis, Receptors, Immunologic, Biological
Markers, Inflammation Mediators, Carrier Proteins/
blood, Membrane Glycoproteins/blood, Acute-Phase
Proteins, sTREM-1, soluble Triggering Receptor Expressed
on Myeloid cells (see Additional file 1: Search strategy).
Publications of regulatory agencies such as the European
Medicines Agency (EMA) (scientific guidelines, European
public assessment reports of authorized products, opinions
of paediatric investigation plans already adopted by the
paediatric committee) were examined to describe how the
biomarker had been considered for regulatory purposes.
To expand our search, references of the retrieved arti-
cles and reviews were hand-searched for additional stud-
ies. No lower date limit was set and the search was
continued until August 2015. No language limit was
used.
Selection criteria
All studies or subsets of studies on paediatric patients
with an assessment of sTREM-1 as a diagnostic test for
sepsis were eligible for inclusion.
We excluded articles not within the scope of this re-
view, review articles, editorials or letters, comments,
conference proceedings, case reports and studies in pa-
tients over 18 years of age. Two groups of authors inde-
pendently reviewed the articles to assess their eligibility.
Disagreements were resolved in a consensus meeting.
Data extraction
For each study, data concerning the publication (authors,
journal, and year of publication), patients and compari-
sons (gender, age, diagnosis, outcomes, methodology)
were collected systematically and independently by two
groups of authors.
In order to assess the diagnostic value of sTREM-1 in
paediatric sepsis, the following outcomes were extracted:
Sensitivity, Specificity, Positive predictive value (PPV),
Negative predictive value (NPV) and Area Under Re-
ceiver Operating Characteristic (AUC) curve.
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Study quality assessment
Risk of bias in the included studies was assessed inde-
pendently by two groups of authors using the Quality
Assessment Tool for Diagnostic Accuracy Studies
(QUADAS) described in the Cochrane Collaboration
Handbook as a reference guide. This tool allows rating
risk of bias as “low”, “unclear” or “high”. Disagreements
were resolved through discussion.
Results
Selected studies
The literature search retrieved 456 records. Following
the selection process, nine studies (comprising 961 pa-
tients) were identified, four of which had been per-
formed in newborns, three in children and two in
children with febrile neutropenia (Fig. 1). Due to hetero-
geneous study designs, in terms of patient age and use
of different comparators, outcome data could not be
pooled statistically and are presented qualitatively. Study
characteristics are presented in Table 1 and Additional file 2.
Studies in newborns
Sarafidis et al. [17] investigated sTREM-1 for diagnosis
of late onset sepsis, finding higher sTREM-1 levels in
infected patients, with a sensitivity of 70 % and a specificity
of 71 % at a cut-off level of 143 pg/ml. However, IL-6 dem-
onstrated both a higher sensitivity (80 %) and specificity
(81 %). It was not clear in this study if the combined use of
IL-6 and sTREM-1 would have been more powerful.
Schlapbach et al. [18] found that infected newborns
had trend-wise higher sTREM-1 levels (p = 0.05), but
pancreatic stone protein (PSP), procalcitonin (PCT) and
C-reactive protein (CRP) performed better. The sensitiv-
ity of sTREM-1 was 75 %, while the specificity was 52 %.
The AUC for sTREM-1 was comparable to that of CRP,
but PSP and PCT displayed superior performance. Based
on ROC curve analyses, sTREM-1 was included in some
bioscore models, which were constructed employing
two, three or four markers. The bioscore based on PSP
and PCT performed similarly to or better than the bio-
scores including sTREM-1 or CRP, suggesting that nei-
ther sTREM-1 nor CRP provided additional independent
information. Only PSP and PCT worked as independent
predictors of early onset sepsis (EOS) in multivariate lo-
gistic regression models.
Mazzucchelli et al. [19] studied both sTREM-1 and
TREM-1 expression on polymorphonuclear cells (PMNs)
by flow cytometry. The study did not find a statistically
Records identified through database searching (n = 456)
Pubmed (n = 201); ISI Web of Science (n = 209); 
























Records excluded from 
title and abstract
(n = 287)
Full-text articles assessed 
for eligibility
(n = 178)
Full-text articles excluded, with 
reasons
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- 37 reviews or proceedings
- 15 editorials
- 100 studies in adults
- 17 studies not in humans
Studies included in 
qualitative synthesis
(n = 9)
Fig. 1 Flow chart. The flow diagram depicts the flow of information through the different phases of this systematic review on the diagnostic
value of soluble triggering receptor expressed on myeloid cells in paediatric sepsis
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Table 1 Table of included studies (Continued)
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significant increase in median sTREM-1 concentration
during sepsis. However, a significant reduction in the ex-
pression of TREM-1 on PMNs during sepsis was no-
ticed, with a sensitivity of 56.2 % and a specificity of
93.7 %. Data showed that, individually, CD64 was more
reliable than TREM-1 expressed on PMNs in identifying
newborns with late-onset sepsis, with a sensitivity of
87.5 %, a specificity of 100 % and an AUC of 0.95.
Adly et al. [20] found high sensitivity and specificity
for sTREM-1, with an AUC of 1 at a cut-off value of
310 pg/ml. Moreover, they found that sTREM-1, at the
cut-off of 1100 pg/ml, was more sensitive than CRP in
predicting survival.
Studies in children
Chen et al. [21] evaluated sTREM-1 in the diagnosis of
serious bacterial infection (SBI) in febrile infants less
than three months of age. Among SBIs, evidence of
bacteraemia was found in 5 % of the population. Most
patients suffered from urinary tract infections. In these
patients, sTREM-1 at the cut-off level of 24.4 pg/ml
showed a superior accuracy to CRP in predicting SBI,
with a sensitivity of 87 % and a specificity of 81 %
(AUC = 0.88).
Kevan et al. [22] measured the levels of lipopolysacchar-
ide binding protein and sTREM-1 in paediatric patients
with intestinal failure and central venous catheter-
associated bloodstream infections. This case—control
study analysed different infectious episodes in the same
patients. As a result, sTREM-1 levels were increased dur-
ing all infectious episodes but not specifically bacteraemic
episodes.
Carrol et al. [23] studied the accuracy of sTREM-1 and
four additional biomarkers in diagnosing sepsis in chil-
dren presenting with severe infection and high preva-
lence of malaria and HIV. In this case, sTREM-1 was
not superior to CRP and PCT, exhibiting high sensitivity
(87 %), but low specificity (15 %).
Studies in children with febrile neutropenia
Miedema et al. [24] studied sTREM-1 together with
CRP, IL-8 and PCT in childhood cancer patients with fe-
brile neutropenia. The aim of this study was to prove
the diagnostic value of biomarkers in detecting bacterial
infections. sTREM-1 was below the detection limit
(likely because both monocyte and neutrophil counts
were low by definition), and therefore appeared unsuit-
able as biomarker in febrile neutropenia.
Arzanian et al. [25] demonstrated a significant associ-
ation between sTREM-1 levels and the presence of bac-
teraemia and fungaemia in febrile neutropenic patients
with cancer. They used a cut-off point of 525 pg/ml for
sTREM-1 as detected by ELISA. In a population of 65
patients (mean age of five years), they found high
sensitivity (85 %) and specificity (98 %) for sTREM-1 in
the detection of blood infections (AUC = 0.96).
Quality assessment
Assessment of methodological quality of included arti-
cles according to the QUADAS criteria is reported in
Table 2. Six studies presented spectrum bias. This is the
bias originating from the selection of a population that
certainly harbours the disease, which is compared to a
population of unaffected subjects. Under spectrum bias
both sensitivity and specificity are artificially increased,
suggesting an overrated diagnostic accuracy. All studies
were unclear as to whether the reference standard had
been interpreted without prior knowledge of the index
test. Overall, the reference standard had been correctly
defined both in newborns and in children. Selection cri-
teria comprising inclusion and exclusion criteria of each
study are reported in Table 3. We decided to rate a bias
in the QUADAS question for the selection criteria in all
studies that did not clearly report the exclusion criteria
employed.
Discussion
The results of our review show preliminary evidence for
a role of sTREM-1 in the diagnostic workup of sepsis in
newborns and children. It was not possible to obtain
quantitative results due to the small number of studies,
which included heterogeneous populations. We divided
the retrieved studies in three diagnostic categories: stud-
ies in newborns, in children and in children with febrile
neutropenia.
Studies in newborns
The four newborn studies were affected by variability
concerning inclusion criteria: Sarafidis et al. [17]
included late onset sepsis (LOS), Schlapbach et al. [18]
early onset sepsis (EOS), Adly et al. [20] and
Mazzucchelli et al. [19] included both. Concerning age, a
variable mix of term and preterm babies was included in
three studies, whereas in the study by Mazzucchelli et al.
[19] only preterm babies were included. Two articles
clearly disclosed the exclusion criteria: Adly et al. [20]
and Sarafidis et al. [17] both left out congenital abnor-
malities or congenital infections, Sarafidis et al. [17] ex-
cluded babies born from mothers with chorioamnionitis
and Adly et al. [20] excluded babies previously treated
with intravenous immunoglobulin. In three studies,
sTREM-1 plasma concentration was evaluated by ELISA.
In the study by Mazzucchelli et al. [19], sTREM-1 dos-
age correlated weakly with the diagnosis of sepsis,
whereas a strong correlation was found for the cyto-
fluorimetric evaluation of TREM-1 membrane expres-
sion on neutrophils and monocytes. Relevant differences
were found in terms of methodology: two out of four
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studies [19, 20] were affected by spectrum bias. This
was clearly mirrored by the very high AUC: 80 % in
Mazzucchelli et al. [19] and even 100 % in Adly et al. [20],
much higher than the AUC observed in the other two
studies: 73 % for Sarafidis et al. [17] and 62 % for
Schlapbach et al. [18]. Actually, in Schlapbach et al.
[18], sTREM-1 accuracy was comparable to that of
CRP and PSP (62 % vs 66 % and 69 %, respectively),
but was much lower than PCT (77 %). sTREM-1
might have been more accurate in EOS than in LOS,
but a well-designed study would be needed; the evalu-
ation of a biomarker combination (such as PCT +
TREM) could also be of interest in order to assess a
possible gain in accuracy and cost-effectiveness.
Studies in children
The three studies in children were characterized by a
high variability among clinical conditions. Chen et al.
[21] included infants less than three months of age with
suspected serious bacterial infection, including urinary
tract infections, pneumonia, positive blood or cerebro-
spinal fluid culture, reporting a higher accuracy of
sTREM-1 (AUC 88 %) as compared to CRP or the
immature-to-total neutrophil ratio. Kevan et al. [22] in-
cluded a population of paediatric intestinal failure pa-
tients with central venous catheters and evaluated the
role of sTREM-1 in device-associated bloodstream infec-
tions: in this setting, sTREM-1 showed poor discriminat-
ing power for bacteraemia (AUC 57 %), probably
because of the strong confounding factor of the impaired
intestinal wall. The last study [23] was carried out in a
developing country, thus being subject to the peculiar
epidemiological features of such context, primarily a
high prevalence of HIV, which in fact affected about
50 % of the patients. sTREM-1 performed no better than
CRP (AUC 50 % vs. 52 %) and far worse than PCT
(81 %) in this environment.
Studies in children with febrile neutropenia
Two studies were performed in children with febrile
neutropenia. In these studies SIRS was not employed as
an inclusion criterion, because chemotherapy-induced
neutropenia represents per se a condition of increased
susceptibility to infections, requiring prompt clinical
evaluation. The two studies showed different results: in
Arzanian et al. [24], a very high cut-off value for
sTREM-1 was used, resulting in a high accuracy in diag-
nosing bacteraemia and fungaemia in febrile neutropenic
patients, whereas in Miedema et al. [25], sTREM-1 ac-
curacy could not be evaluated since sTREM-1 appeared
to be undetectable at presentation in most patients.
Limitations
Like other systematic reviews of diagnostic tests, our
work has some limitations. Firstly, The included studies
opted for very different sTREM-1 cut-off values and
measuring techniques (Table 1 and Additional file 2);
Secondly, publication bias (lower probability of publica-
tion of negative results) is known to be more difficult to
avoid in observational studies of diagnostic tests than in
Table 3 Selection criteria of the single studies
Inclusion criteria Exclusion criteria
Chen et al. 2008 Febrile infants < 3 months with suspected serious bacterial
infection (SBI): UTI, pneumonia, positive CSF or blood colture.
Not disclosed.
Carrol et al. 2009 Children with suspected Serious Bacterial Infection
(meningitides or Pneumonia) of a Malawian Hospital.
Age: 2 months–16 years.
Significant co-existing morbidity.
Sarafidis et al. 2010 Admission to a NICU of a single university hospital for
suspected Late Onset Sepsis (LOS) >3 days.
Mothers with clinical chorioamnionitis; early-onset sepsis;
congenital infections or anomalies.
Kevan et al. 2011 Pediatric intestinal failure (IF) patients with central venous
catheter (CVC) of a children hospital. Age: between 3 months
and 4 years.
Small bowel, liver/small bowel, or multivisceral transplant;
known underlying immune disorder; current diagnosis of
infection other than CVC-BSI; immune suppressant
medications or systemic antibiotics for more than 24 hours
before inclusion.
Miedema et al. 2011 Febrile neutropenia and oncological underlying disease. Not disclosed.
Arzanian et al. 2011 Fever >38 °C for at least one hour or >38,3° in a single
measurement; absolute neutrophil count of less than 500/mm3.
Patients under treatment with GCSF; patients already on
antibiotics before the beginning of fever and neutropenia
except for prophylaxis.
Schlapbach et al. 2013 Neonates >34 weeks admitted within the first 72 h with
suspicion of sepsis (Early onset sepsis).
Not disclosed.
Mazzucchelli et al. 2013 Gestational age younger than 32 weeks and/or birth weigh
less than 1500 g free of infection.
Not disclosed.
Adly et al. 2014 Newborns with clinical and laboratory signs of sepsis. Congenital infections; malformations; major chromosomal
abnormalities; prior use of intravenous immunoglobulins.
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randomized controlled trials [26]; Thirdly, in several
studies blinding of reference standard results and the
‘blindness’ of study design were not fully reported;
Fourthly, no article reported if the reference standard re-
sults had been interpreted without prior knowledge of
the results of the index test; Fifthly, several studies were
affected by spectrum bias; Sixthly, given that different
methodologies were used, it was not possible to perform
a meta-analysis, nor were we able to obtain a pooled es-
timate of accuracy for sTREM-1.
Conclusions
A specific marker for the early detection of paediatric
sepsis would be highly desirable. Reviewed data support
a role of sTREM-1 as a diagnostic tool in this setting,
but cannot be considered conclusive. Some evidences
suggest that the determination of sTREM-1 in combin-
ation with other biomarkers could achieve a better per-
formance than each biomarker alone. Indeed, it would
be very important to standardize measuring techniques
in order to achieve more robust and comparable results.
Recent diagnostic developments, such as multiplex bead
array assays, offer promising opportunities [27].
We believe that large, prospective studies exploring
the role of sTREM-1would be necessary to overcome
heterogeneity and inconsistent results.
We recommend to:
1) Harmonize methodology (using agreed case
definitions of suspected and confirmed sepsis, Early
and Late Onset Sepsis);
2) Investigate combination of sTREM-1 with other bio-
markers, such as CRP, PCT, TNF-alpha or IL-6, and
a scoring system bridging clinical and laboratory
findings.
At present, sTREM-1 should be considered an inter-
esting exploratory biomarker for paediatric sepsis.
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